Winners and losers from Washington’s drug pricing agenda – By Bob Herman (Axios) / Nov 27 2019
The Senate’s drug pricing bill would likely be better for the pharmaceutical industry than either President Trump’s agenda or House Speaker Nancy Pelosi’s.
Between the lines: Industry opposes anything that would hurt its bottom line, but of those three proposals, the Senate’s “is a positive tradeoff,” analyst Ronny Gal of AllianceBernstein wrote to investors this week.
Between the lines: The Senate bill could take some political heat off the industry, while Pelosi’s bill and Trump’s proposal to tie Medicare’s prices to international prices would make bigger changes to the actual system.
How it works: The international pricing index and Senate bill both only focus on Medicare, but would change different parts of Medicare.
Continue to article: https://www.axios.com/drug-pricing-proposals-medicare-pharma-companies-a2ab25b5-15f7-4d4e-bbc4-96830c022c07.html
Illustration: Sarah Grillo/Axios
